Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 3/20 | 0.43 |
| ▸ | STK17B | O94768 | 1/20 | 0.39 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.33 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5786509 | 0.86 | NUDT1 (0.45) | NUDT1STK17BSTK17AALDH1A1L3MBTL1 | |
| Hydrochloric Acid SCHEMBL5788283 | 0.84 | NUDT1 (0.44) | NUDT1STK17BSTK17AALDH1A1L3MBTL1 | |
| SCHEMBL1938007 | 0.81 | STK17A (0.50) | NUDT1STK17BSTK17AALDH1A1L3MBTL1 | |
| SCHEMBL4137651 | 0.79 | NUDT1 (0.51) | NUDT1STK17BSTK17AALDH1A1L3MBTL1 | |
| SCHEMBL30718893 | 0.79 | MEN1 (0.46) | NUDT1STK17BSTK17AALDH1A1L3MBTL1 | |
| SCHEMBL4134213 | 0.79 | MEN1 (0.46) | NUDT1STK17BSTK17AALDH1A1L3MBTL1 | |
| SCHEMBL5772371 | 0.78 | STK17B (0.38) | NUDT1STK17BSTK17AALDH1A1L3MBTL1 | |
| SCHEMBL5789412 | 0.76 | NUDT1 (0.42) | NUDT1STK17BSTK17AALDH1A1L3MBTL1 | |
| SCHEMBL5431524 | 0.74 | STK17B (0.45) | NUDT1STK17BSTK17AMAPK8JAK2 | |
| SCHEMBL5787248 | 0.74 | MAPK8 (0.43) | NUDT1STK17BSTK17ACTSLCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070197510-A1 | Nitriles and medicinal compositions containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-08-23 | — | — | US | disclosed |
| EP-1724264-A1 | NITRILES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-11-22 | — | — | EP | disclosed |
| EP-1423121-B1 | CYSTEINE PROTEASE INHIBITORS WITH 2-CYANO-4-AMINO-PYRIMIDINE STRUCTURE AND CATHEPSIN K INHIBITORY ACTIVITY FOR THE TREATMENT OF INFLAMMATIONS AND OTHER DISEASES | NOVARTIS AG (CH) | 2006-11-15 | — | — | EP | disclosed |
| US-7112589-B2 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases | NOVARTIS AG (CH) | 2006-09-26 | — | — | US | disclosed |
| US-20060074092-A1 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin K inhibitory activity for the treatment of inflammations and other diseases | ALTMANN EVA | 2006-04-06 | — | — | US | disclosed |
| US-20040249153-A1 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases | NOVARTIS AG (CH) | 2004-12-09 | — | — | US | disclosed |
| EP-1423121-A1 | CYSTEINE PROTEASE INHIBITORS WITH 2-CYANO-4-AMINO-PYRIMIDINE STRUCTURE AND CATHEPSIN K INHIBITORY ACTIVITY FOR THE TREATMENT OF INFLAMMATIONS AND OTHER DISEASES | Novartis AG (CH) | 2004-06-02 | — | — | EP | disclosed |
| WO-2003020278-A1 | CYSTEINE PROTEASE INHIBITORS WITH 2-CYANO-4-AMINO-PYRIMIDINE STRUCTURE AND CATHEPSIN K INHIBITORY ACTIVITY FOR THE TREATMENT OF INFLAMMATIONS AND OTHER DISEASES | NOVARTIS AG (CH) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197510-A1 | Nitriles and medicinal compositions containing the same as the active ingredient | CTRL, NOS1, CPN1 | NUDT1 619/4885STK17B 3095/4885STK17A 2502/4885 |
| US-20040249153-A1 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases | CTSK, CTSS, CTSZ | NUDT1 1614/4885STK17B 587/4885STK17A 442/4885 |
| US-20060074092-A1 | Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin K inhibitory activity for the treatment of inflammations and other diseases | CTSK, CTSS, CTSZ | NUDT1 1583/4885STK17B 584/4885STK17A 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.